Evidence map›Paper›PMID 29593859›Full record

ArticleTherapeutic advances in drug safety2017

A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease.

Gregory Fusco, Ali Hariri, Carlos Vallarino, Ajay Singh, Peter Yu, Lesley Wise

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in drug safety, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Gregory FuscoEpividian, Inc., 4819 Emperor Boulevard, Suite 400, Durham, NC 27703, USA.
Ali HaririSanofi Pharmaceuticals, Inc., Bridgewater, NJ, USA.
Carlos VallarinoTakeda Pharmaceuticals International Inc., Deerfield IL, USA.
Ajay SinghBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Peter YuTakeda Pharmaceuticals International Inc., Deerfield IL, USA.
Lesley WiseWise Pharmacovigilance and Risk Management, Ltd., UK.
Takeda (United States) · USBrigham and Women's Hospital · USSanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess cardiovascular risk among various hemoglobin (Hb) rates of rise (RoR) in chronic kidney disease (CKD) patients with anemia who have initiated therapy with erythropoiesis stimulating agents (ESAs).

methodsObservational cohort of CKD patients initiating ESA therapy from the Centricity

resultsA total of 9220 patients receiving ESAs were followed for an average of 3.1 years. Slow (group B) RoR

conclusionRapid Hb rise is associated with adverse CV outcomes, with markedly lower risk for rates below a threshold trajectory of 0.125 g/dl/month, even with complete correction.

Indexed as

chronic kidney disease anemiaerythropoiesis stimulating agentshemoglobin rate of risehemoglobin reconstitutionhyporesponsivenessmanagement ofthreshold trajectory

Identifiers

PMID29593859
PMCPMC5865462
OpenAlexW2755669522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.